Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3709910 | 0.84 | GLA (0.38) | ALDH1A1LMNAGLANPSR1BACE1 | |
| SCHEMBL3708994 | 0.82 | ALDH1A1 (0.41) | ALDH1A1LMNAL3MBTL1GLANPSR1 | |
| SCHEMBL3713259 | 0.79 | GLA (0.60) | ALDH1A1L3MBTL1GLANPSR1HSD17B10 | |
| SCHEMBL3708565 | 0.78 | HSD17B10 (0.40) | ALDH1A1LMNAPOLBGLANPSR1 | |
| SCHEMBL15570301 | 0.74 | GLA (0.67) | ALDH1A1LMNAL3MBTL1MDM2POLB | |
| SCHEMBL3097535 | 0.71 | GLA (0.48) | ALDH1A1LMNAL3MBTL1MDM2POLB | |
| SCHEMBL7026943 | 0.70 | ALDH1A1 (0.40) | ALDH1A1LMNAL3MBTL1MDM2POLB | |
| SCHEMBL4262330 | 0.69 | GSK3B (0.43) | ALDH1A1LMNAL3MBTL1MDM2GLA | |
| SCHEMBL3705561 | 0.68 | GLA (0.48) | ALDH1A1LMNAPOLBGLANPSR1 | |
| SCHEMBL4365447 | 0.68 | POLB (0.44) | ALDH1A1LMNAL3MBTL1MDM2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742139-B2 | No-carrier-added nucleophilic [F-18] fluorination of aromatic compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-06-03 | — | — | US | disclosed |
| US-20120123120-A1 | No-Carrier-Added Nucleophilic [F-18] Fluorination of Aromatic Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123120-A1 | No-Carrier-Added Nucleophilic [F-18] Fluorination of Aromatic Compounds | SLC18A1, SLC18A2, SLC6A2 | ALDH1A1 842/4885LMNA 2451/4885L3MBTL1 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.